Drug factory · FDA FEI 1000548067

Minakem Beuvry Production

145, Chemin des Lilas, Beuvry la Foret, France

France: 1

Problems found, fixed voluntarily at FDA's last inspection, Mar 11, 2022.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

5 drug inspections on record since 2010: 0 with no problems, 5 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
MetyraponeMakes the active ingredient and tests it Esteve Pharmaceuticals, S.a., HRA Pharma Rare Diseases 68118-455, 76336-455

FDA inspection history

EndedResultProgramProblems noted
Mar 11, 2022Problems found, fixed voluntarilyDrug Quality Assurance—
Jan 25, 2018Problems found, fixed voluntarilyDrug Quality Assurance—
Mar 25, 2016Problems found, fixed voluntarilyDrug Quality Assurance—
Sep 13, 2013Problems found, fixed voluntarilyDrug Quality Assurance—
Jul 8, 2010Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture.